ArticleFrontiers in immunology2018
A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 3 pooled it
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- A systematic review and meta-analysis of circulating serum and plasma microRNAs in TB diagnosis.BMC infectious diseases · 2024Pooled it
- MicroRNAs as diagnostic biomarkers for Tuberculosis: A systematic review and meta- analysis.Frontiers in immunology · 2022Pooled it
- Diagnostic accuracy of Mycobacterium tuberculosis cell-free DNA for tuberculosis: A systematic review and meta-analysis.PloS one · 2021Pooled it
- Different MicroRNAs expression inRNA biology · 2026Review
- Evaluation of extracellular microRNAs as potential biomarker candidates for assessing chlamydia reinfection risk.PloS one · 2026Article
- Diagnostic performance of circulating microRNA signatures for differentiating tuberculosis disease from tuberculosis infection.Medical microbiology and immunology · 2025Article
- Serum microRNA Biomarker Expression in HIV and TB: A Concise Overview.Infectious disorders drug targets · 2025Review
- Significance of extracellular vesicles in orchestration of immune responses inFrontiers in cellular and infection microbiology · 2024Review
- Discovery of a blood-based miRNA signature that can predict onset of active tuberculosis among household contacts of TB patients.Frontiers in tuberculosis · 2024Article
- Reduction of Biosensor False Responses and Time Delay Using Dynamic Response and Theory-Guided Machine Learning.ACS sensors · 2023Article
- Advances in computational frameworks in the fight against TB: The way forward.Frontiers in pharmacology · 2023Review
- Non-Coding RNAs in Tuberculosis Epidemiology: Platforms and Approaches for Investigating the Genome's Dark Matter.International journal of molecular sciences · 2022Review
- Subsequent AS01-adjuvanted vaccinations induce similar transcriptional responses in populations with different disease statuses.PloS one · 2022Article
- Observational
- microRNAs associated with the pathogenesis and their role in regulating various signaling pathways duringFrontiers in cellular and infection microbiology · 2022Review
- Can miRNA Indicate Risk of Illness after Continuous Exposure toInternational journal of molecular sciences · 2021Article
- Systematic evaluation, verification and comparison of tuberculosis-related non-coding RNA diagnostic panels.Journal of cellular and molecular medicine · 2021Article
- Review
- CircAGFG1modulates autophagy and apoptosis of macrophages infected by Mycobacterium tuberculosis via the Notch signaling pathway.Annals of translational medicine · 2020Article
- MicroRNA Biomarkers for Infectious Diseases: From Basic Research to Biosensing.Frontiers in microbiology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 6 countries.
Fergal J DuffyThe Center for Infectious Disease Research, Seattle, WA, United States.
Ethan ThompsonThe Center for Infectious Disease Research, Seattle, WA, United States.
Katrina DowningSouth African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Sara SulimanSouth African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University, Kampala, Uganda.
W Henry BoomCase Western Reserve University, Cleveland, OH, United States.
Bonnie ThielCase Western Reserve University, Cleveland, OH, United States.
January Weiner IiiMax Planck Institute for Infection Biology, Berlin, Germany.
Stefan H E KaufmannMax Planck Institute for Infection Biology, Berlin, Germany.
Drew DoverThe Center for Infectious Disease Research, Seattle, WA, United States.
David L TabbDST/NRF Centre of Excellence for Biomedical TB Research and MRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Hazel M DockrellDepartment of Immunology and Infection, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Tom H M OttenhoffDepartment of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
Gerard TrompDST/NRF Centre of Excellence for Biomedical TB Research and MRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative, Division of Immunology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.
Daniel E ZakThe Center for Infectious Disease Research, Seattle, WA, United States.
Gerhard WalzlDST/NRF Centre of Excellence for Biomedical TB Research and MRC Centre for TB Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa.
GC6-74 Consortium
Stellenbosch University · ZACase Western Reserve University · USCenter for Infectious Disease Research · USInfectious Disease Research Institute · USMax Planck Institute for Infection Biology · DESouth African Tuberculosis Vaccine Initiative · ZALeiden University Medical Center · NLLondon School of Hygiene & Tropical Medicine · GBMakerere University · UGUniversity of Cape Town · ZA
Funding
TR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsP41GM109824 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2014 to 2023
$18.8MNew Tools for Exploring the Dynamic Interactome (Renewal)U54GM103511 · NIGMS · ROCKEFELLER UNIVERSITY · PI ROUT, MICHAEL P · 2012 to 2013
$6.2MNIGMS NIH HHS P41 GM109824NIGMS NIH HHS U54 GM103511
Abstract
Biomarkers that predict who among recently
Indexed as
AdolescentAdultBiomarkersCirculating MicroRNAContact TracingDisease ProgressionFemaleHumansMachine LearningMaleMycobacterium tuberculosisRiskSouth AfricaTuberculosis, PulmonaryUgandaYoung AdultBiomarkersCirculating MicroRNAbiomarkercorrelate of riskhousehold contactmachine learningmicroRNAtuberculosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.